Skip to content

Board of Directors

For more information, please contact us.

For more information, please contact us.

Daniel D. Burgess, Chairman

Mr. Burgess was founder, President and CEO of Rempex Pharmaceuticals Inc., an antibiotic company that was sold to the Medicines Company.  Previously, Mr. Burgess was President and CEO of Mpex Pharmaceuticals Inc., a company that advanced an inhaled antibiotic for cystic fibrosis into Phase 3 before it was acquired by Aptalis Inc. in 2011.  Mr. Burgess has also held senior executive positions at a number of other biotechnology companies and served as a Director and Chairman of the Audit Committee of Santarus Inc. until its acquisition by Salix Inc. in 2014.

Erez Chimovits, Senior Managing Director, Orbimed Israel

Mr. Chimovits is a Managing Director. Erez has 14 years of operational experience, including 10 years of senior managerial experience in public companies. Prior to joining OrbiMed Erez was the CEO of NasVax (TASE: NSVX). NasVax acquired Protea and struck agreements with GlaxoSmithKline and Novartis. Previously, Erez spent more than seven years with Compugen (Nasdaq:CGEN), as President, Compugen USA Inc. and Executive VP, Commercial Operations. At Compugen, he had P&L responsibility for more than 100 people and led multiple transactions including J&J, Novartis, Teva, Abbott, Medarex and others. In addition to Atox Bio, Erez is a board member at AdicetBio, FutuRx, LogicBio, Emendo, Novus, Nucleix, NovellusDX, BiomX and Mitoconix.  Erez earned his M.B.A., M.Sc. in Microbiology and his B.Sc. from Tel Aviv University.

Matthew Foy, Partner, SR One

Mr. Foy joined SR One’s London office in 2011. Previously he was a Vice President at Greenhill & Co, an M&A Investment Bank and Private Equity firm in New York. Matthew studied Molecular Biology at The University of Oxford; Drug Discovery at UCL; Corporate Finance at The London Business School and holds various FSA & SEC qualifications. His portfolio companies include AtoxBio, Progenitor, PsiOxus, Pulmocide, Puridify and VHSquared.

Terry Gould, Partner and Head of Venture/Growth Investments, Adams Street Partners, LLC

Terry invests in venture and growth-oriented companies with a focus on the healthcare space. Terry sits on the Boards of Directors of Aptinyx, Atox Bio, Corvus Pharmaceuticals (NADSAQ: CRVS), Fusion Pharmaceuticals, LifeBond, Orbus Therapeutics, and Outpost Medicine. He is a Board Observer at Millendo. He is a former board member at CombiChem, INC Research, Incline Therapeutics, OncoMed (NADSAQ: OMED), and Proteus Digital Health. He is responsible for several other successful investments including Heartport, Jazz Pharmaceuticals, Naurex Pharmaceuticals, NxStage Medical, Pharmacyclics, Rempex Pharmaceuticals, Revivant, Spinal Dynamics and Vivant Medical. Before joining in Adams Street in 1994, Terry was with Trinity Ventures, Ltd. and spent five years as a management consultant, including experience with the Boston Consulting Group, an international strategy consulting firm. He also has experience as a founder and executive in two successful entrepreneurial companies. Terry is a graduate of Dartmouth College, BA and Stanford University Graduate School of Business, MBA.

Dane Ross, Managing General Partner, Belay Equity

Mr. Ross has been an Atox Bio Board Director since early 2012, serving as the Company’s Chairman 2013-14. Dane started VC in 1995 with DLJ’s (Credit Suisse) VC affiliate Sprout Group, and was 8 years with Elwin Capital Partners. Dane was also the Chairman of International Management Ventures. Previously, he was with Denmark’s Carl Bro Group’s software subsidiary System Data. Dane Ross is alum of the Kauffman Venture Capital Fellows Charter Class, the first of 19 classes of 350+ Kauffman VC Fellows & Mentors managing 300+ funds and $200+ billion. Dane also has 25+ years of CEO experience, 7 years as dual CEO/ COO. Dane earned an MBA and a Lebor/ Arthur Rock Entrepreneur Fellowship at the Harvard Business School, and a Bachelors- International Business- University of Minnesota and DIS Program/ Copenhagen University, Denmark.

Mark Chin, Managing Director, Arix Bioscience

Mark is an experienced venture capital investor, with significant experience as a board director of both private and public biotech companies in the US and Europe. Mark sourced and led Arix investments into key portfolio companies, including: VelosBio (acquired by Merck for $2.75bn), Amplyx Pharmaceuticals (acquired by Pfizer), Aura Biosciences, Harpoon Therapeutics (Nasdaq IPO) and Imara (Nasdaq IPO). He is currently a Board Director of Harpoon Therapeutics, Inc. (Nasdaq: HARP), Imara Inc. (Nasdaq: IMRA) and Iterum Therapeutics plc (Nasdaq: ITRM). Mark was previously a principal at Longitude Capital, where he focused on investments in biotechnology and medical technology companies. Prior to Longitude, he was a consultant at the Boston Consulting Group, where he was responsible for strategy and corporate development projects for pharmaceutical and biotechnology companies. Before BCG, he worked in corporate development at Gilead Sciences and market planning at Genentech. He has an MBA from The Wharton School at the University of Pennsylvania, an MS in Biotechnology from the University of Pennsylvania, and a BS in Management Science from the University of California at San Diego.

Thomas Tan

Dr. Tan joined the Atox Bio Board of Directors in 2021. Prior to Lundbeckfonden Ventures, he advised leading pharma and biotech companies on strategy, competitive intelligence and market access. Thomas did his doctorate at The University of Oxford and his M.Sc. at Copenhagen University.